Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Methenolone** is a synthetic androgen and anabolic steroid (AAS) used primarily in the form of esters (metenolone acetate and metenolone enanthate) for the treatment of anemia due to bone marrow failure and conditions involving muscle wasting. The drug acts as an agonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone (DHT), exhibiting moderate anabolic and weak androgenic effects. Methenolone itself is not commonly used therapeutically, as only its esters are marketed clinically. It has no estrogenic effects or risk of liver toxicity, and side effects primarily involve masculinization. Methenolone was developed in the late 1950s, mainly by Schering, and is mostly discontinued today, with most medical use now being in the form of its esters[3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenolone.